Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | PPM1B | O75688 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | FPR1 | P21462 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496344 | 0.86 | ALDH1A1 (0.71) | LMNAKMT2AALDH1A1MEN1BLM | |
| SCHEMBL13311757 | 0.83 | ALDH1A1 (1.00) | LMNAKMT2AALDH1A1MEN1BLM | |
| SCHEMBL3493983 | 0.83 | ALDH1A1 (1.00) | LMNAKMT2AALDH1A1MEN1BLM | |
| SCHEMBL3496402 | 0.83 | ALDH1A1 (0.78) | LMNAKMT2AALDH1A1MEN1BLM | |
| SCHEMBL3495475 | 0.82 | ALDH1A1 (0.76) | LMNAKMT2AALDH1A1MEN1BLM | |
| SCHEMBL3500228 | 0.82 | ALDH1A1 (0.76) | LMNAKMT2AALDH1A1MEN1BLM | |
| SCHEMBL3493897 | 0.82 | KMT2A (0.76) | LMNAKMT2AALDH1A1MEN1BLM | |
| SCHEMBL13311427 | 0.80 | ALDH1A1 (0.72) | LMNAKMT2AALDH1A1MEN1BLM | |
| SCHEMBL3924044 | 0.80 | PPM1B (0.68) | KMT2AALDH1A1MEN1TDP1PPM1B | |
| SCHEMBL3496110 | 0.78 | GAA (0.71) | LMNAKMT2AALDH1A1MEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
| EP-2086534-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | Genetic Technologies Limited (AU) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008058342-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | PPP1R10, TASP1, PPP5C | LMNA 4332/4885KMT2A 1199/4885ALDH1A1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.